Unihealth Hosp (UNIHEALTH)

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding at 69.53% aligns management with minority shareholders and signals commitment.
• Sales growth of 54.08% and profit growth of 195.12% show a company in rapid expansion.
• PEG of 0.17 suggests the current P/E is attractive relative to the profit growth rate.
• Piotroski F-Score 7/9 indicates healthy financial fundamentals and improving profitability.
• ROCE of 17.15% is respectable, suggesting efficient use of capital.

Concerns

• Trailing P/E of 21.02 implies ~₹24 Cr TTM profit, but the latest quarter alone shows ₹29 Cr net profit; this mismatch questions earnings sustainability.
• No dividend yield means investors must rely entirely on future capital appreciation.
• Key balance-sheet metrics like book value, ROE and debt/equity are unavailable, so debt and asset quality cannot be assessed.
• Current price is ~40% below the 52-week high of ₹819 and well above the low, indicating significant volatility.

AI Analysis

Numbers are a starting point, not a conclusion. Unihealth's top line grew 54.08% and profit grew 195.12%; those are impressive rates, and a PEG of 0.17 suggests the market is not paying enough for that growth. Promoter holding of 69.53% is good; owners have skin in the game. Piotroski score of 7/9 and ROCE of 17.15% also indicate a fundamentally improving business. However, I need to understand the quality of these numbers. The market cap is ₹507 Cr and P/E is 21.02, which implies trailing earnings of roughly ₹24 Cr. But the latest quarter alone shows net profit of ₹29 Cr. That inconsistency tells me the quarterly profit is not a clean recurring run-rate; it may include unusual items or reflect a lumpy hospital business. Profit growth of 195% from a low base is easy to overpraise. There is no dividend, so my return depends completely on management reinvesting the profits wisely—and I cannot verify that because book value, ROE, and debt-equity are not available. For a hospital, debt and capital expenditure matter. Without those, my margin of safety is thin. The 52-week range of ₹133.65 to ₹819.00 shows this is a volatile stock; today's price of ₹492.25 is far off the high and well above the low. FairStock Score of 55/100 calls it steady, but I don't pay for labels. I would want several more quarters of consistent earnings, better balance-sheet disclosure, and evidence that growth can be converted into durable free cash flow before calling it a wonderful business at a fair price.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer